Navigation Links
FDA Orders Warning Label on Older Antipsychotics
Date:6/16/2008

Drugs increase risk of death among elderly patients with dementia, agency says

MONDAY, June 16 (HealthDay News) -- The U.S. Food and Drug Administration is cautioning physicians that certain types of antipsychotic drugs can boost the death risk of seniors with dementia.

Doctors sometimes use antipsychotics to help treat behavioral problems in demented patients.

But from now on these older, so-called "conventional" antipsychotics -- which include drugs such as thorazine and prolixin -- will carry a new black box warning alerting physicians of the danger, FDA officials announced Monday.

"We issued letters to all the manufacturers of antipsychotic drugs, both conventional and atypical, requiring them to update their labeling with new language for a box warning about an increased risk of death in elderly patients with dementia," Dr. Thomas Laughren, director of the FDA's Division of Psychiatry Products at the Center for Drug Evaluation and Research, said during an afternoon teleconference.

This is a new warning for conventional antipsychotics, but it is not new for another class of the medications, called atypical antipsychotics. Back in 2005, the FDA ordered warning labeling for those medications, which include newer drugs such as Zyprexa and Risperdal. That labeling warned of a higher risk for heart attack and pneumonia for elderly patients with dementia who received atypical antipsychotics.

This new black box warning for older, conventional antipsychotics is one of the first uses by the agency of the Food and Drug Administration Amendments Act of 2007, which gives the FDA authority to mandate drug warnings, something they could only request before.

According to Laughren, the FDA based its 2005 decision on a review of studies comparing their use to a placebo. At the time, a lack of evidence prevented the agency from extending the warning to conventional antipsychotics, Laughren said.

However, since then, observational studies have appeared that indicate that conventional antipsychotics carry the same risk, he said. "The data we have for observational studies are not ideal, so we struggled with this decision, but in the end decided that the data were strong enough to extend the warning to all drugs in this class," he said.

When looking at the data involving atypical antipsychotics, the FDA found that over 10 weeks, roughly 4.5 percent of patients with dementia taking these drugs died, compared with 2.6 percent of patients receiving a placebo, Laughren said.

Laughren noted that all these patients were very ill in their 80s and in nursing homes. The deaths appeared to be mostly from cancer or infections such as pneumonia.

One study by Canadian researchers, published in May in the Archives of Internal Medicine, found that elderly patients with dementia given atypical antipsychotics were 3.2 times more likely than individuals who had received no antipsychotic therapy to be hospitalized or to die during 30 days of follow-up.

Conventional antipsychotics, as well as atypical antipsychotics, are not approved for use in elderly patients with dementia, Laughren noted.

"Patients with dementia often have behavioral symptoms as well. They can have psychotic symptoms, such as delusions and hallucinations, they can be agitated, aggressive and at times violent, and antipsychotic drugs are sometimes used in treating these behavioral symptoms," Laughren said.

"We are not telling physicians that they absolutely cannot use these drugs in this setting," he added. "What we want to do is make them aware of this risk. This is something we hope they would discuss with the families and caregivers so they can understand that there are risks to using these drugs."

Both conventional and atypical antipsychotics are dopamine receptor agonists that work by blocking the action of dopamine in the brain. The primary differences between them are side effects, which are fewer among the atypical antipsychotics.

More information

For more on antipsychotic drugs, visit the U.S. Food and Drug Administration.



SOURCES: June 16, 2008, teleconference with Thomas Laughren, M.D., director, Division of Psychiatry Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Plaintiffs Lawyer Orders Lead Testing on 3 Popular Herbalife Products; Results Show 728% More Lead Than Allowed by Law Under Proposition 65 Violation
2. Childrens Neck Size Associated With Sleep Disorders
3. Combat Vets Display Severe Sleep Disorders
4. Beyond Traditional Borders sends more Rice U. undergrads to Africa
5. Risk Factors for Eating Disorders Vary by Gender
6. Autism Author and Psychologist Dr. Jed Baker to Speak on Communication Disorders
7. Experts to discuss sleep science and the health risks of sleep disorders in Baltimore this June
8. New Treatment Guide for Eating Disorders Available to Healthcare Professionals
9. At the synapse: Gene may shed light on neurological disorders
10. Green Tea May Help Brain Cope With Sleep Disorders
11. The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Orders Warning Label on Older Antipsychotics
(Date:7/26/2017)... ... ... The number of adults 65 years or older is expected to more than ... the population are not well described. In a study published in The Journal of ... American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified factors associated with asthma-related ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Haller, to the sales department joining as Regional Account Manager for the Northeast ... contracted customers in the liquidation of their obsolete medical assets. , Jennifer joins ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... clients, today announced it will be exhibiting and providing demos of its smart ... Walter E. Washington Convention Center in Washington D.C. from August 3-6, 2017. , ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... as medical director. Dr. Negrette has more than a decade of experience in ... worked closely with individuals fighting addictions, eating disorders, psychotic and manic conditions, as ...
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South Austin ... area 24 Hours a day. , The Emergency Room opened early ... been open four months now and things are running smoothly,” said Aaron Braun, SignatureCare ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment ... in 2021, according to Medical Equipment & ... by Freedonia Focus Reports. Continued increases in demand for ... aging of the population and supported by gains in ... equipment and supplies. New product introductions will also drive ...
(Date:7/10/2017)... 10, 2017  The tenth annual BioPharm America™ ... at the Sheraton Boston Hotel, September 26–27. ... to global decision makers and innovative biotech startup companies. ... leaders during two impactful days. BioPharm America is now ... additional networking opportunities with 4,500+ life science industry influencers ...
Breaking Medicine Technology: